New research highlighted by Medscape suggests that the asthma drug omalizumab may allow patients with food allergies to skip the slow build-up phase of oral immunotherapy (OIT) and go straight to a maintenance dose.
According to Medscape, the approach, described as omalizumab-facilitated OIT, could change how doctors manage multifood allergies. The report indicates that using omalizumab before or during treatment may let patients reach a stable, protective dose faster than the traditional method, which typically requires gradual increases over many months.
The findings, also covered by HCPLive and Medical Republic, point to a potential advantage over standard multiallergen oral immunotherapy. Medical Republic reported that omalizumab outperformed the conventional approach for treating allergies to multiple foods at once. This is significant because many patients with severe food allergies react to more than one food, making standard OIT complex and time-consuming.
The core idea is that omalizumab, which blocks immunoglobulin E (IgE), can reduce allergic reactions enough to allow a patient to start at a higher dose of the food protein. This could cut the number of clinic visits and the overall time needed to reach a protective level. Medscape’s coverage frames this as a possible shift toward a more efficient treatment model.
However, the reports do not specify the exact study size, patient demographics, or the precise dosing protocols used. The full data has not been published in the summaries provided.
What to watch next: Whether larger trials confirm that direct-to-maintenance dosing with omalizumab is safe and effective across different age groups and food allergens.
